USPTO serial 79143546
B PURUI
Reviewed by CopyMark Law Group
Reg. 4634904Status 404
- Filing date
- Status date
- Registration date
- Nov 11, 2014
- Examiner
- CLARK, ROBERT C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with B PURUI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Xianju Pure Pharmaceutical Co., Ltd
Xianju, Zhejiang, CN
Other trademarks owned by Xianju Pure Pharmaceutical Co., Ltd
Xianju Pure Pharmaceutical Co., Ltd
Xianju, Zhejiang, CN
Other trademarks owned by Xianju Pure Pharmaceutical Co., Ltd
Zhejiang Pure Pharmaceutical Co., Ltd.
CN
Other trademarks owned by Zhejiang Pure Pharmaceutical Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John Alumit
John Alumit ALUMIT IP135 S. Jackson Street, Suite 200Glendale, CA 91205UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations in injection, tablet, and liquid for treating allergic rhinitis and asthma, diabetes, skin disorders, allergies, hypertension; Chinese Medicine in the nature of medicinal herbs; Medicinal alcohol; Pesticides; Hormones, namely, Eplerenone for treating hypertension; Fluticasone Propionate for preventing and treating allergic rhinitis; topical corticosteroid preparations, namely, diflucortolone for topical corticosteroids anti-inflammatory; Deflazacort for treating adrenal cortical hypofunction, autoimmune disease, allergic diseases and diseases of the blood system, Betamethasone for treating allergic and autoimmune inflammatory diseases, active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, and acute leukemia; Dexamethasone for treating autoimmune diseases, allergy, inflammation, asthma and ophthalmology disease; Dexamethasone for treating Inflammatory and allergic diseases; Dexamethasone sodium phosphate for treating fever, 6-methyl prednisolone for treating inflammation; steroid hormones, namely, cortisol for treating adrenal insufficiency, arthritis pauperum, rheumatic fever, arthrolithiasis, bronchial asthma, allergic dermatitis, seborrheic dermatitis, pruritus, iridocyclitis, conjunctivitis, keratitis, scleritis, tuberculous meningitis, arthritis, pleurisy, tenosynovitis, acute and chronic sprain, and tendon strain; Hydrocortisone Acetate for treating rheumatic arthritis, acute articular rheumatism, arthrolithiasis, bronchial asthma, tuberculous, purulent meningitis, tuberculous pleurisy, pyothorax, arthritis, peritendinitis, sprain, hyde's disease, and lichen planus; Medroxyprogesterone Acetate for treating algomenorrhea, functional amenorrhea, dysfunctional uterine bleeding, threatened abortion and habitual abortion, endometriosis uterine, mammary cancer, adenocarcinoma of endometrium, and renal carcinoma; Cyproterone Acetate for treating prostatic carcinoma, hirsutism, and androgenetic alopecia; Prednisolone for treating allergic and inflammatory diseases; Prednisolone Acetate for treating dermatitis, eczema, lichen planus circumscriptus, seborrheic dermatitis, rheumatism, arthritis deformans, Biett's disease, bronchial asthma, dropsical nephritis, essential thrombopenia, granulocytopenia, acute lymphatic leukemia, adrenal insufficiency, and dermatitis exfoliativa; Astenile for treating advanced cervix mature insufficiency; Trenbolone Acetate for treating chronic wasting disease, ill and frail thin, frail after operation, osteoporosis, children dysplasia, and aplastic anemia; Stanazolol for treating hereditary angioneurotic edema, and cacotrophy; Oxymetholone for treating chronic wasting disease, infirm, sick and postoperative weak thin, nausea, edema, liver dysfunction and jaundice; Estradiol for treating estrogen deficiency, metastatic breast cancer, advanced prostate cancer, acne, aleucocytosis, and postcoital contraception; Estriol for treating cervicitis, auxiliary medicine and abortion of midtrimester induction of labor, prostatauxe, prostatic carcinoma, aleucocytosis, and haemorrhage | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Xianju Pure Pharmaceutical Co., Ltd
- Other trademarks owned by Xianju Pure Pharmaceutical Co., Ltd
- Other trademarks owned by Zhejiang Pure Pharmaceutical Co., Ltd.
- Other trademarks in Class 005
- Similar marks named B PURUI
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 23, 2024 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Jun 23, 2024 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Jul 11, 2022 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| May 24, 2022 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| May 23, 2022 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Jan 28, 2022 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| May 28, 2021 | C71T | CANCELLED SECTION 71 | — |
| Nov 11, 2019 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Nov 17, 2016 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Apr 24, 2015 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 6, 2015 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 6, 2015 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 11, 2015 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 11, 2014 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 26, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 26, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 22, 2014 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Aug 6, 2014 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 6, 2014 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 6, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 23, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 17, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 16, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 15, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 15, 2014 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jul 11, 2014 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 11, 2014 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 11, 2014 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 27, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 27, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 16, 2014 | ALIE | ASSIGNED TO LIE | — |
| Jun 6, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 4, 2014 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 14, 2014 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 14, 2014 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 14, 2014 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 13, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 13, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 12, 2014 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 8, 2014 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 6, 2014 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |